Stiri	Stiri afaceri	Stiri companii	Evenimente de afaceri

The pharma market went up by 8.4% reaching 500 million euro in Q2

The annual growth rhythm of the pharma market reached 8.4% in Q2 after Q1 was 6.1%, according to the market research company Cegedim.

Cegedim calculates the annual growths comparing the current quarter and the last three quarters to the similar period of the previous year.  The pharma market in Romania went up by 8.4% over the last four quarters, up to 6.46 billion lei ( almot 1.8 billion euros) as compared to the same period of 2006 – 2007, according to Cegedim. “ The second quarter of 2008 meant a coming back of the growth rate of the whole market (8.4% against 6.1% at the end of Q1, compared to 11.2% at the end of 2007)” the Cegedim communiqué published on Moday says.

 All in all, the pharma market confirmed the previous evolutions. Thus, on the distribution channels, the retail market went up ( +14.6%) as compared to the hospital one which registered a drop ( - 9.7%)over the last four quarters, as compared to the previous four quarters. ” Part of this variation is due to the change of some national health programs from hospital to retail last year” the Cegedim specialists explained. On segments, medical prescription medicine went up more speedily than the ones without prescription ( + 16.3%, + 8.1% respectively). The prescription medicine market ( Rx) was worth 1.2 billion lei ( 333 million euros) in Q2, and the sales of over the counter medicine (OTC) went up to 298.2 million lei ( almost 83 million euros) over the analysed period.

The majority of the therapeutical groups had  a growing trend. The most important were in antineoplasic and immunomodular ( + 26.7%), muscular-skeletal  system ( +15.8%), cardiovascular system ( +13.3%). On the other hand, there were therapeutical groups with slow evolution, such as anti-infectious systemic ( = 2.5%), digestive system and metabolism ( +2.9) and dermatologie (+4.1%). The first place in the top of drug production in Q2 was occupied by Hoffman La Roche with sales of 130 million lei ( 36 million euros) representing 7.2% out of the total. GlaxoSmithKline (GSK) with sales of 118.2 million ( 32.8 mil.euro) representing almost 7% out of the total of the market was ranked 2. On the next places there were Sanofi-Aventis, Novartis and Servier with sales of over 100 million lei ( 28 mill.euro). Pfizer, Ranbaxy, Zentiva and Krka DD were ranked on the following places with sales of over 50 million lei ( 14 million euros) over Q2. Antibiotice Iasi was ranked 10th with sales of 49.1 million lei ( 13.6 mil.euro) over the analysed period.

« The troubles of the last months on the pharma market make us be careful about what regards the perspectives on a short term. Although the perspectives on a medium term are positive, the present blockage may lead to supplementary difficulties to the companies on the market” mentioned the Cegedim representatives. They estimated the market will close the current year with a performance close to the present one of OTC drugs ( 8%) in the context where the stoppage of prices influences the market of prescribed drugs, irrespective of the therapeutical group or producer and the impact of the new lists of compensated drugs is not felt yet.

Sursa: http://www.actmedia.ro

Tags: market euros sales cegedim euro million pharma

Articole similare